In turn, the combination with chemotherapy or ionizing radiation can increase sensitivity to BCL‐2 inhibitors in preclinical tumor cell lines and patient samples by a reduction in MCL‐1 levels.7, 14, 16. This evidence concerns the gene BCL2 and neoplasm.